Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 53
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Active
18 and over
Other
2006-00055-18
NCT00415103
Last Modified:
6/9/2008
 
First Published:
9/26/2007
2.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
4 and over
NCI
RPCI-I-72806
I 72806, NCT00536601
Last Modified:
11/11/2008
 
First Published:
8/1/1997
3.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
15 to 65
NCI
SWOG-S9704
CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
Last Modified:
3/14/2008
 
First Published:
3/1/2001
4.
Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
CKTO-2000-06
HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
Last Modified:
7/1/2008
 
First Published:
3/24/2004
5.
Phase III Randomized Study of Rituximab, Ifosfamide, Carboplatin, and Etoposide Versus Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Induction Therapy Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With Versus Without Rituximab as Maintenance Therapy in Patients With Relapsed or Refractory CD20-Positive Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
NCI
MSKCC-03139
CORAL-50-03B, NCT00137995
6.
Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 65
Other
MCL2004-2
NCT00209222
7.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 80
NHLBI
384
BMT CTN 0401, U01 HL069294-05, NCT00329030
Last Modified:
6/19/2008
 
First Published:
2/5/2007
8.
Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Diagnostic, Treatment
Active
Under 18
Other
EURONET-PHL-C1
EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10
9.
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
65 and under
Other
2005-001110-41
NCT00461747
10.
Zevalin and BEAM High-Dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin’s Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Approved-not yet active
18 to 65
Other
Sor451107ctil
NCT00463463
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute